O'Connor R - Search Results

1

Modulation of P-gp expression by lapatinib.

Dunne G, Breen L, Collins DM, Roche S, Clynes M, O'Connor R. Dunne G, et al. Invest New Drugs. 2011 Dec;29(6):1284-93. doi: 10.1007/s10637-010-9482-7. Epub 2010 Jul 6. Invest New Drugs. 2011. PMID: 20607587

2

Recent developments in drug resistance and apoptosis research.

Clynes M, Daly C, NicAmhlaoibh R, Cronin D, Elliott C, O'Connor R, O'Doherty T, Connolly L, Howlett A, Scanlon K. Clynes M, et al. Crit Rev Oncol Hematol. 1998 Sep;28(3):181-205. doi: 10.1016/s1040-8428(98)00018-3. Crit Rev Oncol Hematol. 1998. PMID: 9793746 Review. No abstract available.

3

Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs).

Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O'Loughlin CM, NicAmhlaoibh R, Clynes M. Duffy CP, et al. Eur J Cancer. 1998 Jul;34(8):1250-9. doi: 10.1016/s0959-8049(98)00045-8. Eur J Cancer. 1998. PMID: 9849488

4

Synthesis of indomethacin analogues for evaluation as modulators of MRP activity.

Maguire AR, Plunkett SJ, Papot S, Clynes M, O'Connor R, Touhey S. Maguire AR, et al. Bioorg Med Chem. 2001 Mar;9(3):745-62. doi: 10.1016/s0968-0896(00)00292-3. Bioorg Med Chem. 2001. PMID: 11310610

5

Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition. identification of novel chemotherapeutic drug resistance modulators.

Touhey S, O'Connor R, Plunkett S, Maguire A, Clynes M. Touhey S, et al. Eur J Cancer. 2002 Aug;38(12):1661-70. doi: 10.1016/s0959-8049(02)00128-4. Eur J Cancer. 2002. PMID: 12142058

6

Methods for generation of monoclonal antibodies to the very small drug hapten, 5-benzimidazolecarboxylic acid.

Moran E, O'Keeffe M, O'Connor R, Larkin AM, Murphy P, Clynes M. Moran E, et al. J Immunol Methods. 2002 Dec 20;271(1-2):65-75. doi: 10.1016/s0022-1759(02)00340-x. J Immunol Methods. 2002. PMID: 12445730

7

Challenges in molecular analysis for individualized cancer therapy.

Clynes M, O'Connor R, O'Driscoll L, Daly C, Meleady P. Clynes M, et al. Drug Discov Today. 2003 Jun 15;8(12):531. doi: 10.1016/s1359-6446(03)02730-2. Drug Discov Today. 2003. PMID: 12821298 No abstract available.

8

Induction of apoptosis in yeast and mammalian cells by exposure to 1,10-phenanthroline metal complexes.

Coyle B, Kinsella P, McCann M, Devereux M, O'Connor R, Clynes M, Kavanagh K. Coyle B, et al. Toxicol In Vitro. 2004 Feb;18(1):63-70. doi: 10.1016/j.tiv.2003.08.011. Toxicol In Vitro. 2004. PMID: 14630063

9

Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer.

O'Connor R, Heenan M, Connolly L, Larkin A, Clynes M. O'Connor R, et al. Anticancer Res. 2004 Mar-Apr;24(2A):457-64. Anticancer Res. 2004. PMID: 15152944 Free article.

10

Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs.

Liang Y, O'Driscoll L, McDonnell S, Doolan P, Oglesby I, Duffy K, O'Connor R, Clynes M. Liang Y, et al. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230. Int J Cancer. 2004. PMID: 15239124 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,210 results

Search Page